文章核心观点 - 艾克拉瑞斯治疗公司是一家临床阶段的生物制药公司,专注于开发针对免疫炎症性疾病的新药候选药物 [1][3] - 公司拥有多阶段的药物候选品组合,由强大的研发引擎探索蛋白激酶调节 [3] - 公司将于2024年5月7日发布2024年第一季度财务业绩报告,并在同日举行电话会议提供公司更新 [1][2] 公司信息 - 艾克拉瑞斯治疗公司是一家上市的临床阶段生物制药公司 [1][3] - 公司专注于开发针对免疫炎症性疾病的新药候选药物,以满足患者的未满足治疗需求 [3] - 公司拥有多阶段的药物候选品组合,由强大的研发引擎探索蛋白激酶调节 [3] - 公司将于2024年5月7日发布2024年第一季度财务业绩报告,并在同日举行电话会议提供公司更新 [1][2]

Aclaris Therapeutics (ACRS) - Aclaris Therapeutics (ACRS) 是医疗行业的一员，目前在Zacks Sector Rank 中排名第4位[2] - ACRS 目前的 Zacks Rank 为 2 (Buy)，过去一个季度，ACRS 的全年盈利预期上调了13.9%[3] - ACRS 今年以来的回报率为9.5%，高于医疗行业的平均回报率7.3%[4] ASLAN Pharmaceuticals Ltd. (ASLN) - ASLAN Pharmaceuticals Ltd. (ASLN) 今年以来的股价上涨了36%，目前的 Zacks Rank 为 2 (Buy)[5] - ASLAN Pharmaceuticals Ltd. 属于医疗-生物医学和遗传学行业，该行业今年以来上涨了0.1%[7] 行业表现比较 - ACRS 属于医疗-药品行业，该行业今年以来平均下跌了1.3%，但 ACRS 的表现更好[6] 投资建议 - 投资者应该继续关注 Aclaris Therapeutics 和 ASLAN Pharmaceuticals Ltd.，因为它们可能会继续表现良好[8]

文章核心观点 - 根据Zacks评级系统,Aclaris Therapeutics(ACRS)公司被评级为Zacks Rank 2(买入),这主要反映了该公司的盈利预测呈上升趋势,这是影响股价的最强大力量之一[1][4][6] - Zacks评级系统主要依据公司未来盈利前景的变化,通过分析分析师对该公司当前及未来一年盈利预测的共识来进行评级[2][3][7] - 盈利预测的变化对股价走势有很强的相关性,因为机构投资者会根据盈利预测来计算公司股票的合理价值,并据此进行买卖操作,从而带动股价的变动[5] - Aclaris公司盈利预测的上升意味着其基本面有所改善,投资者应该认可这一积极趋势并推动股价上涨[6] - Zacks评级系统能有效利用盈利预测修正这一强大信号,在过去30年里,Zacks Rank 1(强烈买入)的股票年均收益达25%[7][8] 公司情况 - Aclaris Therapeutics是一家专业制药公司,预计2024财年每股收益为-0.98美元,同比增长36.8%[9] - 过去3个月内,分析师对Aclaris公司的盈利预测不断上调,Zacks共识预测上升了15.5%[10] 行业情况 - 无相关内容

Aclaris Therapeutics (ACRS) - Aclaris Therapeutics (ACRS) 是医疗组中排名第四的公司[2] - Aclaris Therapeutics 目前的Zacks Rank为2 (Buy)，全年盈利预期上调15.5%[3] - ACRS 今年以来的回报率为18.1%，高于医疗股平均回报率7.5%[4] Aldeyra Therapeutics, Inc. (ALDX) - Aldeyra Therapeutics, Inc. (ALDX) 今年以来的股价上涨了20.2%[5] - Aldeyra Therapeutics, Inc. 目前的Zacks Rank为2 (Buy)，全年盈利预期上调58%[6] 行业比较 - Aclaris Therapeutics 和 Aldeyra Therapeutics, Inc. 都属于医疗-药品行业，该行业今年以来平均回报率为3.1%[7] 投资建议 - 投资者应继续关注 Aclaris Therapeutics 和 Aldeyra Therapeutics, Inc.，因为它们可能会保持良好的表现[8]

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.92%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.48 per share when it actually produced a loss of $0.41, delivering a surprise of 14.58%.Over the last four quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-37581 ACLARIS THERAPEUTICS, INC. Incorporated under the Laws of the I.R.S. Employer Identification No. State of Delaware 46-0571712 701 Lee Road, Suite 103 Wayne, PA 19087 (484) 324-7933 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class: Tradin ...

Shares of Aclaris Therapeutics, Inc. (ACRS) were up 25.4% on Jan 16 after the company announced the appointment of Neal Walker as the new interim chief executive officer (CEO). Walker will replace Douglas Manion, who stepped down from his role with immediate effect. He also served as the president of the company and was a member of the board of directors.Walker is currently serving as the chairman of the company and is also a co-founder. He held the role of Aclaris' CEO until 2022.Along with the leadership ...

- Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive Officer - WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced leadership changes and that it is undertaking a strategic review of its busines ...

Proactive公司概况 - Andrew Kessel是一位有丰富经验的金融记者，涵盖了多个行业，包括科技、医药、加密货币、矿业和零售[2] - Proactive是一家提供快速、易于获取、信息丰富且可操作的商业和金融新闻内容的公司，由经验丰富的新闻记者团队独立制作[3] - Proactive的新闻团队遍布全球主要的金融和投资中心，拥有办事处和工作室[4] Proactive公司业务范围 - Proactive团队专注于中小市值市场，同时也让社区了解蓝筹公司、大宗商品和更广泛的投资故事[5] - Proactive团队提供市场上跨领域的新闻和独特见解，包括生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术[6] Proactive公司工作流程 - Proactive一直是一个前瞻性和热情的技术采用者，团队拥有许多年宝贵的专业知识和经验，同时也利用技术来辅助和增强工作流程[7] - Proactive偶尔会使用自动化和软件工具，包括生成式人工智能，但所有由Proactive发布的内容都是由人类编辑和撰写的，符合内容制作和搜索引擎优化的最佳实践[8]

- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports "Soft" Topical JAK Inhibitor Approach - - ATI-1777 Was Well Tolerated - WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its Phase 2b study of ATI-1777, an investigationa ...